Startups
Dove Medical Press
Edit

Dove Medical Press

Trusted
http://www.dovepress.com/
Last activity: 27.07.2026
Active
Categories: HealthTechMedTechMessangerOnlinePublisherPublishingResearchScienceServiceTechnology
Dove Medical Press Ltd is an online open access academic publisher specialising in science, technology and especially medicine. All 90+ peer-reviewed journals are free to access online, allowing authors to disseminate their research to a global audience. Most of our journals are widely indexed in databases such as PubMed, Scopus and DOAJ, and an increasing number have Impact Factors.

We are a member of OASPA, COPE and HINARI, and are committed to publishing good scientific research and giving authors around the world the opportunity to publish and share their research findings.

We have an efficient and rigorous peer-review process. Due to this, many of our journals are able to provide authors with an initial editorial decision within four to five weeks. We aim to provide the highest possible standard of service to our authors. Recent feedback from an author survey demonstrated that:

• 100% of authors surveyed found the online manuscript system easy to use
• 100% of authors surveyed agreed that they received professional accurate service
• 97% of authors surveyed would submit a manuscript with us again
• 96% of authors surveyed received prompt communication throughout the publishing process
• 86% of authors surveyed rated their level of satisfaction as Excellent (the other 14% rated us as good)

To view testimonials from more of our authors please visit: https://www.dovepress.com/testimonials.php

We have offices in the United Kingdom, USA and New Zealand.

Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC
Likes
11.72K
Followers
3.17K
Website visits
1.3M /mo.
Mentions
64

Overview

Location
New Zealand, Auckland
Employees
51-200
Phone
+44 1625 509130
Founded date
2003

Mentions in press and media 64

DateTitleDescription
Sign up to seeSign up to seeSign up to see
Mar 23, 2026Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting AntibodyCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 23, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery and development of novel antibody the...
Feb 9, 2026Mann Eye Institute Study Demonstrates Exceptional Visual Outcomes with Next-Generation TECNIS Odyssey LensHOUSTON, TX, UNITED STATES, February 9, 2026 /EINPresswire.com/ -- Mann Eye Institute, a leading eye care provider serving Houston and Austin for over four decades, has published groundbreaking research on visual outcomes following bilatera...
Oct 16, 2025NXTSTIM’s EcoAI™ Backed by Largest 24-Month Real-World Dataset in Pain TherapyDr. Bart Billet treating a patient with NXTSTIM’s EcoAI™ Landmark 24-month study of over 2,100 patients shows EcoAI™ delivers long-term pain relief and functional improvement with zero adverse events. SAN DIEGO, CA, UNITED STATES, October 1...
Jul 7, 2025New Study Finds Sahaj Samadhi Meditation Effective for Managing Depression in Chronic Pain PatientsWASHINGTON, DC, UNITED STATES, July 7, 2025 /EINPresswire.com/ -- A newly published clinical study has found that Sahaj Samadhi Meditation™, a technique taught by The Art of Living Foundation for over four decades, offers meaningful relief ...
Nov 12, 2024AstraZeneca and Daiichi Sankyo Forge Ahead with Datopotamab Deruxtecan Amid Regulatory ShiftsIn the fast-paced world of oncology, AstraZeneca and Daiichi Sankyo are navigating the complex landscape of drug approval with their latest offering, datopotamab deruxtecan (Dato-DXd). This investigational drug is aimed at treating advanced...
Nov 12, 2024AstraZeneca's Bold Moves: New Approvals and Major InvestmentsAstraZeneca is making waves in the pharmaceutical world. The company recently submitted a new Biologics License Application (BLA) for datopotamab deruxtecan, a promising treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mu...
Nov 12, 2024Dato-DXd new BLA submitted, NSQ BLA withdrawnDato-DXd new BLA submitted, NSQ BLA withdrawn Tue, Nov 12, 2024 08:00 CET Report this content 12 November 2024 Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mu...
Jun 4, 2024Elemind’s neurotech headband puts you to sleep when you wantGamesBeat is excited to partner with Lil Snack to have customized games just for our audience! We know as gamers ourselves, this is an exciting way to engage through play with the GamesBeat content you have already come to love. Start playi...
Apr 16, 2024Health | As AI eye exams prove their worth, lessons for future tech emergeHannah Norman | (TNS) KFF Health News Christian Espinoza, director of a Southern California drug-treatment provider, recently began employing a powerful new assistant: an artificial intelligence algorithm that can perform eye exams with pic...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In

FAQ about Dove Medical Press

When was Dove Medical Press founded?

Dove Medical Press was founded in 2003.

What has the press written about Dove Medical Press?

Parsers VC has collected 64 articles mentioning Dove Medical Press, among them “Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody” (Mar 23, 2026) and “Mann Eye Institute Study Demonstrates Exceptional Visual Outcomes with Next-Generation TECNIS Odyssey Lens” (Feb 9, 2026).

Is Dove Medical Press still active?

Yes, Dove Medical Press is active; its latest activity on Parsers VC dates from Jul 27, 2026.